



NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA OR THROUGH U.S. NEWSWIRE SERVICES

June 9, 2016

BELEAVE ANNOUNCES CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

June 9, 2016, Toronto, ON – Beleave Inc. (the "**Corporation**" or "**Beleave**") wishes to announce that it has closed a second tranche of a private placement financing (the "**Financing**") for gross proceeds of \$28,000. Upon closing the Financing, Beleave issued 93,333 units (each a "**Unit**") at a price of \$0.30 per Unit. Each Unit consists of one common share ("**Common Share**") and one Common Share purchase warrant ("**Warrant**"). Each Warrant is exercisable for one Common Share at a price of \$0.50 for a period of two years from closing.

About Beleave

Beleave Inc. is a biotech company committed to becoming a licensed producer under the *Marihuana for Medical Purposes Regulations* (the "**MMPR**"). Beleave's wholly owned subsidiary First Access Medical Inc. ("**FAM**") has applied for a licence to cultivate and sell medical marihuana pursuant to the MMPR. As of the date hereof, FAM has successfully advanced past the security clearance stage and is currently in the review stage of the licensing process. Beleave's purpose built facility is located near Hamilton, Ontario. Beleave is traded on the CSE under the symbol BE, with 17,380,823 common shares outstanding (25,541,826 on a fully diluted basis).

For more information contact:

Sebastian de Kloet
Phone: 1 (905) 979 - 5173
Email: Sebastian@beleave.com